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Abstract 
White matter hyperintensities (WMHs) are associated with poorer brain health, 
but their pathophysiological substrates remain elusive. To better understand the 
mechanistic underpinnings of WMHs among older adults, this study examined in vivo 
cerebrospinal fluid biomarkers of β-amyloid42 deposition (Aβ42), hyperphosphorylated 
tau pathology (p-tau), neurodegeneration (total tau), and axonal injury (neurofilament 
light; NFL) in relation to log-transformed WMHs volume. Participants free of clinical 
stroke and dementia were drawn from the Vanderbilt Memory & Aging Project (n=148, 
72±6 years). Linear regression models adjusted for age, sex, race/ethnicity, education, 
intracranial volume, modified Framingham Stroke Risk Profile (excluding points 
assigned for age), cognitive diagnosis, and APOE-ε4 carrier status. Aβ42 (β=-0.001, 
p=0.003) and NFL (β=0.0003, p=0.02) concentrations related to WMHs, but neither p-
tau nor total tau associations with WMHs reached statistical significance (p-
values>0.21). In a combined model, NFL accounted for 3.2% of unique variance in 
WMHs and Aβ42 accounted for an additional 4.3% beyond NFL, providing novel 
evidence of the co-occurrence of at least two distinct pathways for WMHs among older 
adults, including amyloidosis and axonal injury.  
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1. Introduction 
White matter hyperintensities (WMHs) are nonspecific radiographic markers of 
fluid accumulation that appear on T2-weighted MRI. Prevalent among community-
dwelling older adults (Garde et al., 2000; Ylikoski et al., 1995), WMHs relate to an 
increased incidence of clinical dementia (Benedictus et al., 2015; Debette et al., 2010; 
Provenzano et al., 2013) and stroke (Debette et al., 2010). Cerebral small vessel 
disease is traditionally the most common etiology attributed to WMHs in older adults 
(Provenzano et al., 2013), but emerging evidence suggests multiple pathological 
pathways are likely (Gouw et al., 2011). Among older adults with prodromal and clinical 
Alzheimer’s disease (AD), increased WMHs relate to in vivo amyloid aggregation as 
measured by PET (Grimmer et al., 2012; Kandel et al., 2016; Marnane et al., 2016; 
Provenzano et al., 2013) and cerebrospinal fluid (CSF) β-amyloid42 (Aβ42) (Marnane et 
al., 2016). Increased WMHs are found in autosomal-dominant AD prior to the onset of 
clinical symptoms, suggesting a link between WMHs and AD pathophysiology (Lee et 
al., 2016). Increased tau aggregation has also been linked to WMHs (Hertze et al., 
2013; Marnane et al., 2016; Tosto et al., 2015), albeit less consistently than amyloid 
aggregation (Kester et al., 2014; van Westen et al., 2016). Collectively, these data 
suggest there may be an AD-specific pathway contributing to WMHs among older 
adults.  
CSF biomarkers have become increasingly recognized for their diagnostic and 
prognostic utility in the study of AD and related dementias (Olsson et al., 2016). CSF 
comes in direct contact with the extracellular compartment of the brain. Therefore, 
analysis of CSF can provide in vivo information about biochemical changes associated 
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with pathophysiological processes and may enhance insight into the neural correlates of 
WMHs. Aβ42 and hyperphosphorylated tau (p-tau) are well-established CSF biomarkers 
associated with AD while total tau (t-tau) is a well-established CSF biomarker of 
neurodegeneration (Blennow et al., 2010). Neurofilament light (NFL) is a non-disease-
specific CSF biomarker for large-caliber axonal injury (Skillback et al., 2014). Figure 1 
provides an illustration of the pathophysiology of AD and neuronal injury associated with 
changes in concentrations for each of these four CSF biomarkers of interest (Aβ42, p-
tau, t-tau, and NFL). Despite emerging evidence that reduced CSF Aβ42 (Kester et al., 
2014; Marnane et al., 2016) and increased CSF NFL (Bjerke et al., 2014; Jonsson et al., 
2010) may correlate with higher WMHs volume among older adults, it is unknown 
whether the variance explained by these two biomarkers is unique or overlapping. 
Furthermore, p-tau and t-tau associations with WMHs warrant further investigation given 
inconsistent findings to date (Kester et al., 2014). 
The current study relates in vivo CSF biomarkers of AD pathophysiology (Aβ42, p-
tau), neurodegeneration (t-tau), and axonal injury (NFL) to fluid attenuated inversion 
recovery (FLAIR)-assessed cerebral WMHs. We hypothesized that Aβ42 and NFL would 
relate to WMHs among older adults. If WMHs reflect heterogeneous AD-specific and 
non-AD-specific pathophysiological substrates, then biomarkers of AD pathogenesis 
(Aβ42) and non-AD-specific axonal damage (NFL) should account for separate variance 
in WMHs. Therefore, in secondary analyses, we hypothesized that Aβ42 and NFL would 
account for unique variance in WMHs. Given the mixed literature regarding p-tau and t-
tau associations with WMHs (Kester et al., 2014; Marnane et al., 2016), we 
hypothesized that p-tau and t-tau would have weak associations with WMHs. The 
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novelty of our work lies in our inclusion of competitive analytical models incorporating 
both Aβ42 and NFL. These models assess whether each biomarker is associated with 
WMHs and whether the variance in WMHs accounted for by each biomarker is 
overlapping or independent of the other. This approach provides a more integrated 
understanding of the underlying CSF biochemical changes that occur in the context of 
WMHs among older adults. Our research also adds to emerging evidence linking CSF 
NFL to brain health outcomes among participant samples enriched for prodromal AD.  
 
2. Materials and methods 
2.1 Participants 
The Vanderbilt Memory & Aging Project (Jefferson et al., 2016) is a longitudinal 
study investigating vascular health and brain aging in a cohort enriched for mild 
cognitive impairment (MCI). Cohort inclusion criteria required participants be age 60 
years and older, speak English, have adequate auditory and visual acuity for testing, 
and have a reliable study partner. At enrollment, participants were excluded for MRI 
contraindication, history of neurological disease (e.g., dementia, multiple sclerosis), 
stroke, heart failure, major psychiatric illness (e.g., schizophrenia), head injury with loss 
of consciousness >5 minutes, and systemic or terminal illness (e.g., cancer) that could 
impact follow-up examination participation. Based on a detailed medical history and 
record review, clinical interview, and neuropsychological assessment, participants were 
labeled at baseline with normal cognition (NC), early MCI (Aisen et al., 2010), or MCI 
(Albert et al., 2011). At enrollment participants completed a comprehensive evaluation 
over 2 or 3 days, including (but not limited to) fasting blood draw, medical history and 
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medication review, physical examination, and multi-modal brain MRI. Participation in a 
fasting lumbar puncture was optional. Participants were excluded from the current study 
if they were missing CSF, covariate, or brain MRI data (see Figure 2 for 
inclusion/exclusion details). The protocol was approved by the Vanderbilt University 
Medical Center Institutional Review Board. Written informed consent was obtained from 
participants prior to data collection. 
2.2 Lumbar Puncture & Biochemical Analyses 
 At baseline, participants were invited to complete an optional fasting lumbar 
puncture procedure. CSF was collected with polypropylene syringes using a Sprotte 25-
gauge spinal needle in an intervertebral lumbar space. Samples were immediately 
mixed and centrifuged, and supernatants were aliquoted in 0.5mL polypropylene tubes 
and stored at -80°C. Samples were analyzed in batch using commercially available 
enzyme-linked immunosorbent assays (Fujirebio, Ghent, Belgium) to determine the 
levels of Aβ42 (INNOTEST® β-AMYLOID(1-42)), p-tau* (INNOTEST® PHOSPHO-
TAU(181P)), and t-tau (INNOTEST® hTAU). P-tau was measured by tagging a tau 
phosphorylation site at amino acid Thr181. This form of phosphorylated tau appears 
most specific to AD and correlates with tangle pathology (Buerger et al., 2006; Seppala 
et al., 2012). NFL was measured using a commercially available enzyme-linked 
immunosorbent assay (Uman Diagnostics). Board-certified laboratory technicians 
processed data blinded to clinical information, as previously described (Palmqvist et al., 
2014). Intra-assay coefficients of variation were <10 percent. 
2.3 Brain MRI 
Participants were scanned at the Vanderbilt University Institute of Imaging 
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Science on a 3T Philips Achieva system (Best, The Netherlands) with 8-channel 
SENSE receiver head coil (Pruessmann et al., 1999). T1-weighted (repetition 
time=8.9ms, echo time=4.6ms, spatial resolution=1x1x1mm3) and T2-weighted FLAIR 
(repetition time=11000ms, echo time=121ms, spatial resolution=0.45x0.45x4mm3) 
images were acquired as part of the larger multimodal neuroimaging protocol. As 
previously published (Jefferson et al., 2016), FLAIR images were post-processed using 
the Lesion Segmentation Tool toolbox for Statistical Parametric Mapping (SPM8) 
(Schmidt et al., 2012) excluding the cerebellum and brainstem. FLAIR images were 
bias-corrected for field inhomogeneities and registered to the T1-weighted images. 
FLAIR intensity distribution of white matter, gray matter, and CSF were assigned, 
enabling detection of outliers. Neighboring voxels were classified iteratively and 
analyzed and assigned to lesion, white matter, or gray matter until no more voxels were 
assigned to a lesion. Scans were individually reviewed and manually corrected for any 
mislabeling. Manual corrections were then confirmed by a board-certified 
neuroradiologist blinded to clinical information (LTD) using the Medical Image 
Processing, Analysis, and Visualization application (http://mipav.cit.nih.gov). Intracranial 
volume was calculated based on a summation of participant-specific grey matter, white 
matter, and CSF using T1-weighted images with SPM8.    
2.4 Analytical Plan 
Systolic blood pressure was the mean of two measurements obtained prior to the 
echocardiogram. Diabetes mellitus was defined as current fasting blood glucose ≥126 
mg/dL, hemoglobin A1C≥6.5%, or current oral hypoglycemic or insulin medication 
usage. Medication review determined anti-hypertensive medication use. Left ventricular 
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hypertrophy was defined on echocardiogram as left ventricle mass index >115 g/m2 in 
men or >95 g/m2 in women. Self-report atrial fibrillation was corroborated by 
echocardiogram, cardiac magnetic resonance imaging, documentation of prior 
procedure/ablation for atrial fibrillation, or medication usage for atrial fibrillation. Current 
cigarette smoking (yes/no within the year prior to baseline examination) was 
ascertained by self-report. Self-report prevalent cardiovascular disease with supporting 
evidence from medical records included coronary heart disease, angina, or myocardial 
infarction (note, heart failure was an exclusion for the parent study). Framingham Stroke 
Risk Profile (FSRP) score was calculated by applying points by sex for age, systolic 
blood pressure accounting for anti-hypertensive medication usage, diabetes mellitus, 
current cigarette smoking, left ventricular hypertrophy, prevalent cardiovascular disease, 
and atrial fibrillation (D'Agostino et al., 1994). We excluded points assigned for age 
since age was included as a separate covariate in our statistical models. APOE 
genotyping was performed on whole blood samples. Apolipoprotein E 4 (APOE4) 
status was defined as positive (ε2/ε4, ε3/ε4, ε4/ε4) or negative (ε2/ε2, ε2/ε3, ε3/ε3). 
APOE2 status was defined as positive ε2/ε2, ε2/ε3, ε4/ε4) or negative (ε3/ε3, ε3/ε4, 
ε4/ε4). Intracranial volume was calculated using methods described above. WMHs 
(cm3) were log-transformed prior to analyses. 
Unadjusted Spearman rank correlations among CSF biomarkers were assessed. 
For hypothesis testing, linear regression models with ordinary least square estimates 
related each CSF biomarker (Aβ42, p-tau, t-tau, and NFL) to log WMHs. Models were 
adjusted for age, sex, race/ethnicity, education, intracranial volume, cognitive diagnosis, 
and APOE4. Given extensive literature suggesting vascular risk factors increase the risk 
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of WMHs (Fazekas et al., 1988; Lazarus et al., 2005) and clinical AD (Borenstein et al., 
2005; Kivipelto et al., 2005), models were also adjusted for adverse vascular risk using 
a modified version (excluding points assigned for age) of the FSRP (D'Agostino et al., 
1994) to avoid arbitrarily detecting a connection between Aβ42 and WMHs that might be 
due to shared vascular risk factors. A post-hoc linear regression model related those 
CSF biomarkers with significant associations to WMHs as competing predictors using 
identical covariates as the primary models. This competitive model approach assessed 
the extent to which the variance accounted for by an individual biomarker was unique or 
overlapping with another biomarker. Competitive models were repeated including all 
remaining CSF biomarkers as additional covariates in separate models. Post-hoc linear 
regression models related an Aβ42 x NFL interaction term to WMHs. Aβ42 interaction 
terms were also separately run for age, APOE4 allele status (dichotomized by presence 
of at least one  allele), APOE2 allele status (dichotomized by presence of at least one 
2 allele), and cognitive diagnosis (NC, MCI) on WMHs. Each model with Aβ42 as the 
predictor was repeated including NFL, NFL + p-tau, and NFL + t-tau as covariates in 
separate models. All models were then repeated stratified by cognitive diagnosis (NC, 
MCI). Significance was set a priori at p<0.05. Analyses were conducted using R 3.1.2 
(www.r-project.org). 
 
3. Results 
3.1 Participant & CSF Biomarker Characteristics 
Participants included 148 adults age 60 to 90 years (72±6 years), 67% were 
men, and 93% self-identified as non-Hispanic White. Aβ42 levels correlated with p-tau 
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(r=-0.21, p<0.01) and t-tau levels (r=-0.25, p<0.001). P-tau and t-tau levels correlated 
(r=0.98, p<0.001). NFL levels correlated with p-tau (r=0.51, p<0.001) and t-tau levels 
(r=0.57, p<0.001). NFL was not associated with Aβ42 (r=-0.06, p=0.49). Participant and 
biomarker characteristics are presented in Table 1. 
3.2 CSF Biomarkers as Individual & Interactive Predictors of WMHs 
In linear regression models, Aβ42 concentrations (p=0.003) and NFL 
concentrations (p=0.02) related to WMHs. A42 did not interact with NFL on WMHs 
(p=0.34). Neither p-tau nor t-tau concentrations were significantly related to WMHs (p-
values>0.21). See Table 2 for effect sizes and Figure 3 for illustrations. 
Aß42 interacted with cognitive diagnosis on WMHs (p=0.03), a finding that 
persisted when NFL was added as a covariate (p=0.009). Stratified analyses revealed 
A42 related to WMHs only in the NC participants (NC p=0.001; MCI p=0.31), which also 
persisted when NFL was added as a covariate (p=0.0004). A42 did not interact with 
age (p=0.88), APOE4 allele status (p=0.50), or APOE2 allele status (p=0.13) on WMHs. 
These interaction models remained null when NFL was added as a covariate (all p-
values>0.09). NFL did not interact with cognitive diagnosis (p=0.68), age (p=0.83), 
APOE4 allele status (p=0.63), or APOE2 allele status (p=0.52) on WMHs. Results were 
similar when including p-tau or t-tau as an additional covariate. See Table 3 for details. 
3.3 CSF Biomarkers as Competing Predictors of WMHs 
In a combined model including the two CSF biomarkers with associations with 
WMHs (i.e., Aβ42 and NFL), both Aβ42 (p<0.001) and NFL concentrations (p=0.006) 
related to WMHs. Covariates accounted for 24.8% of the variance, including 0.5% from 
the modified FSRP. When Aβ42 was added to the model containing just the covariates, it 
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accounted for an additional 3.9% unique variance in WMHs (p=0.007). Adding NFL to 
the model containing just the covariates contributed an additional 3.2% unique variance 
(p=0.01). Adding Aβ42 to the model already containing covariates and NFL contributed 
an additional 4.3% unique variance, resulting in 7.5% combined variance accounted for 
by Aβ42 and NFL beyond covariates. See Table 2 for details. 
 
4. Discussion 
Among community dwelling older adults free of clinical dementia and stroke, we 
found lower CSF Aβ42 and higher CSF NFL related to increased WMHs. When CSF 
Aβ42 and NFL were included as dual predictors in a single model, each biomarker 
statistically accounted for unique variance. However, there was no significant A42 x 
NFL interaction on WMHs. The novelty of this study lies in the use of a single, 
integrated analytical model to concurrently relate multiple CSF biomarkers to WMHs 
assessing the extent to which the variance accounted for by each biomarker is 
overlapping with another biomarker. Our inclusion of an older adult cohort, for which 
two-third of participants were cognitively normal, also addresses a crucial gap in the 
literature regarding the need for more comprehensive biomarker models to predict AD 
and related neurodegeneration in preclinical populations. Prior work has focused 
primarily on the utility of NFL as an individual biomarker of disease progression in 
clinical cohorts. By examining NFL in a competitive analytical model among a non-
demented and predominantly cognitively normal sample, we critically extend the 
literature regarding the additive value of NFL as part of an integrated biomarker model 
in the neurobiology of aging adults. Although cross-sectional, results provide initial 
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evidence suggesting WMHs may reflect distinct neuropathological pathways, including 
both amyloid aggregation and axonal injury. 
Our observation that CSF Aβ42 relates to WMHs (Marnane et al., 2016) after 
adjusting for common confounds, including systemic vascular risk and genetic 
susceptibility to AD, strengthens the hypothesis that an independent Aβ pathway 
contributes to WMHs. The mechanistic link between amyloid and WMHs remains 
elusive but may reflect impaired amyloid clearance through perivascular interstitial fluid 
drainage pathways (Iliff et al., 2012; Kress et al., 2014). Emerging evidence suggests 
drainage systems within the basement membrane of cerebral vessels constitute 
important clearance pathways for amyloid. Aβ particles are prone to aggregate and 
cohere to membrane surfaces, causing them to become trapped alongside immune 
complexes, barricading flow of interstitial fluid (Mawuenyega et al., 2010; Potter et al., 
2013; Zekonyte et al., 2016). This process may result in fluid accumulation and white 
matter disruption appearing as WMHs on FLAIR, with co-occurring evidence of cerebral 
amyloid deposition (Weller et al., 2015). Figure 1 illustrates functional and pathological 
versions of this neural system by which waste products, including insoluble Aβ particles, 
are cleared into interstitial fluid for ultimate removal through the CSF. 
Another important observation from this study is that CSF NFL is associated with 
WMHs even after adjusting for Aβ42 levels, suggesting an axonal injury pathway for 
WMHs unrelated to β-amyloid. Both CSF NFL (Jonsson et al., 2010) and WMHs (Molad 
et al., 2017; Wardlaw et al., 2013) have been linked to small vessel disease, suggesting 
small vessel disease may underlie this association. Our older adult sample was free of 
clinical stroke with limited prevalent cardiovascular disease, and analytical models 
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statistically accounted for systemic vascular risk factors. Therefore, it is unlikely that 
small vessel disease fully accounted for the observed association reported here. The 
pathology underlying WMHs is not completely known and requires further research for a 
more comprehensive understanding. A second possibility is that the co-occurrence of 
axonal damage (represented by increased CSF NFL) and increased WMHs represents 
a heterogeneous set of underlying disease states that result in substantial damage to 
white matter fiber tracts. Regardless of mechanism, CSF NFL elevations correspond 
temporally with acute axonal injury (Bacioglu et al., 2016), so WMHs among older adults 
may signify an active process of white matter tissue breakdown. Given the lack of 
consistent findings regarding histopathological correlates of WMHs (Black et al., 2009; 
Shoamanesh et al., 2011), future studies should longitudinally track temporal 
concordance between changes in CSF NFL and WMHs. Such research could improve 
understanding of whether WMHs persist following a return to baseline in CSF NFL 
concentrations with remission of active white matter injury processes, and whether 
WMHs may represent some threshold of clinical importance regarding CSF NFL 
elevations.  
Consistent with prior literature, neither t-tau (Kester et al., 2014) nor p-tau 
(Guzman et al., 2013) related to WMHs in our sample. Prior literature relating tau 
expression to early axonal injury suggests these associations tend to initiate in the 
perforant pathway and in unmyelinated axons within cortical tissue. Tau associations 
with large-caliber white matter tract damage then occur later in the disease after clinical 
symptoms manifest. In contrast, NFL reflects structural axonal damage regardless of 
disease stage. Thus, in our community-based sample free of clinical dementia, it is not 
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surprising that NFL related more closely to WMHs than tau, since tau expression at this 
preclinical stage is likely more reflective of upstream changes to neuronal health that 
may not yet be sufficient to impact structural axonal damage visible on white matter 
imaging. Underlying mechanisms relating tau protein to white matter damage remain 
unclear, and further study is warranted to elucidate pathogenic substrates of various tau 
biomarkers. 
Our cohort was comprised of older adults free of clinical dementia and stroke, 
two-thirds of whom were cognitively normal. Utilization of a dementia free cohort 
addresses a crucial gap in the literature regarding the need for more comprehensive 
biomarker models to predict AD in preclinical populations. Prior work investigating NFL 
has focused primarily on its utility as an individual biomarker of disease progression in 
clinical populations. By examining NFL in a competitive analytical model among a non-
demented and predominantly cognitively normal sample, we critically extend the 
literature regarding the additive value of NFL as part of an integrated biomarker model 
among a preclinical aging population. 
The current study has several strengths. First, MRI data were collected on a 
single research scanner using T2 FLAIR gold-standard methods for detecting WMHs. 
Both neuroimaging and CSF measurements were processed in core laboratories where 
raters were blinded to clinical information. Potential confounders were ascertained in a 
comprehensive manner, including key covariates that increase cerebral small vessel 
disease and clinical AD risk.  
Despite these strengths, several study limitations are noteworthy, including the 
cross-sectional nature of the methods, which limits drawing conclusions about potential 
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underlying mechanisms. Other limitations include a relatively homogenous participant 
sample in terms of race/ethnicity, and lack of direct method to quantify interstitial fluid 
drainage impairments. Also, covariates in our model accounted for 28.5% of the 
variance in WMHs, and Aβ42 and NFL accounted for an additional 7.5% beyond that. 
Thus, the majority of the variance in WMHs in our sample is due to unknown factors. 
This large proportion of unexplained variance limits our ability to draw mechanistic 
conclusions and speaks to the heterogeneity and ambiguity of WMH substrates in older 
adults, representing an important area for further study. Given the cohort sample 
characteristics (e.g., carefully screened community-based cohort without clinical stroke 
or dementia, most of whom were cognitively normal with a relatively low burden of 
prevalent cardiovascular disease) we would not expect to see a high degree of 
explained variance in WMHs. We speculate findings might become more pronounced 
among more clinically diverse samples of individuals with poorer health characteristics 
and more advanced neurodegenerative disease, representing an important area of 
future investigation. Future research should also explore other biomarkers reflecting 
different pathways of interest (e.g., inflammation, extracellular matrix), which may relate 
to WMHs and provide further insight into the pathological processes underlying WMHs. 
In summary, our findings support the co-occurrence of at least two substrates of 
WMHs among older adults, including distinct amyloid and non-amyloid pathways. This 
observation in a dementia-free sample enriched for mild cognitive impairment suggests 
heterogeneous etiologies underlie development of WMHs prior to clinical manifestation 
of AD and related dementia. Our work highlights the importance of investigating 
neurodegenerative markers in integrative, competitive models rather than studying 
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inherently connected variables in an isolated ‘silo’ approach (Jefferson, 2014). It is 
essential that future research investigate WMHs and emerging dynamic biomarkers to 
better understand the relative contributions of vascular changes or problems (including 
both amyloid and non-amyloid pathways), ex vacuo fluid accumulation from 
neurodegeneration, axonal damage and corresponding demyelination, and other factors 
yet to be identified in the development of WMHs. Specifically, future research should 
investigate possible neuropathological mechanisms underlying the link between CSF 
NFL and WMHs, and leverage human data to corroborate animal models suggesting 
impaired interstitial fluid clearance of Aβ42 may account for the amyloid-dependent 
WMHs pathway we observed. Finally, future studies should employ longitudinal designs 
to elucidate how CSF biomarkers relate to changes in WMHs over time and in 
conjunction with clinical outcomes, including cognitive decline.   
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Table 1. Participant Characteristics 
 n=148 
Demographics & Health Characteristics  
 Age, years 72±6 
 Sex, % male 67 
 Race, % White Non-Hispanic 93 
 Education, years 16±3 
 Cognitive diagnosis, % mild cognitive impairment 38 
 Montreal Cognitive Assessment, total 26±3 
 APOE4, % carriers 33 
 APOE4, % allelles  
 2/2 1 
2/3 8 
2/4 2 
3/3 58 
3/4 22 
4/4 9 
 Framingham Stroke Risk Profile, total* 12±4 
 Systolic blood pressure, mmHg 142±16 
 Anti-hypertensive medication usage, % 46 
 Diabetes, % 17 
 Cigarette smoking current, % 1 
 Prevalent cardiovascular disease, % 3 
 Atrial fibrillation, % 3 
 Left ventricular hypertrophy, % 3 
CSF Biomarker Status & Concentrations, pg/mL  
 Aβ42 718±244 
 Amyloid positive (≤530), % 29 
 T-tau 427±228 
 T-tau positive (≥400), % 43 
 P-tauł 61±26 
 Neurofilament Lightł 1068±581 
Neuroimaging Characteristics  
 Intracranial volume, cm3 1409±128 
 Raw WMHs, cm3 15±19 
 Log-transformed WMHs 2.12±1.13 
Note. Values denoted as mean±standard deviation or frequency; *a modified FSRP 
score was included in statistical models excluding points assigned to age (6.1±2.6); łno 
cut-point available; APOE4=apolipoprotein E 4 allele; WMHs=white matter 
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hyperintensities 
Table 2. Main Effect & Interaction Model Results 
 
R2 
R2 
adjusted 
*Δ R2 
adjusted 
f2 
Partial 
R2 
**P-
value 
†Covariates +       
 Aß42 0.29 0.21 0.02 0.03 0.03 0.007 
 T-tau 0.25 0.19 -0.006 <0.0001 <0.0001 0.34 
 P-tau 0.25 0.19 -0.004 0.002 0.002 0.61 
 NFL 0.28 0.22 0.02 0.04 0.03 0.01 
 Aß42 x NFL 0.31 0.24 0.03 0.06 0.05 0.36 
 Aß42 x age 0.28 0.20 -0.006 0.0001 0.0001 0.71 
 Aß42 x APOE 4 0.28 0.21 -0.003 0.003 0.003 0.65 
 Aß42 x APOE 2 0.30 0.23 0.02 0.04 0.03 0.10 
 Aß42 x diagnosis 0.30 0.23 0.02 0.04 0.04 0.03 
Covariates + NFL +    
 Aß42 0.31 0.24 0.03 0.04 0.04 0.02 
 T-tau 0.28 0.21 -0.004 0.003 0.003 0.55 
 P-tau 0.28 0.22 -0.0002 0.007 0.007 0.33 
 Aß42 x age 0.31 0.24 -0.004 0.003 0.003 0.55 
 Aß42 x APOE 4 0.31 0.24 0.002 0.005 0.005 0.42 
 Aß42 x APOE 2 0.33 0.26 0.02 0.04 0.04 0.10 
 Aß42 x diagnosis 0.34 0.27 0.03 0.05 0.05 0.01 
 NFL x age 0.28 0.22 -0.006 <0.0001 <0.0001 1.00 
 NFL x APOE 4 0.28 0.22 -0.006 0.0002 0.0002 0.87 
 NFL x APOE 2 0.29 0.23 -0.001 0.006 0.006 0.43 
 NFL x diagnosis 0.29 0.23 0.002 0.01 0.01 0.62 
Covariates + NFL + P-tau + 
 Aß42 0.31 0.24 0.03 0.04 0.04 0.02 
 T-tau 0.29 0.21 0.0005 0.007 0.007 0.34 
 Aß42 x age 0.32 0.24 -0.004 0.002 0.002 0.63 
 Aß42 x APOE 4 0.32 0.24 -0.001 0.006 0.006 0.37 
 Aß42 x APOE 2 0.34 0.26 0.02 0.03 0.03 0.11 
 Aß42 x diagnosis 0.34 0.27 0.02 0.05 0.04 0.01 
Covariates + NFL + T-tau + 
 Aß42 0.31 0.24 0.03 0.06 0.04 0.02 
 Aß42 x age 0.31 0.24 -0.004 0.002 0.002 0.61 
 Aß42 x APOE 4 0.32 0.24 0.001 0.006 0.006 0.37 
 Aß42 x APOE 2 0.34 0.26 0.02 0.03 0.03 0.10 
 Aß42 x diagnosis 0.34 0.26 0.03 0.05 0.04 0.01 
Note. *Represents change in R2 from the covariates only model; **For predictor(s) after 
covariates entered into the model; †includes age, education, sex, race/ethnicity, intracranial 
WMH & CSF Biomarkers 29 
 
volume, modified Framingham Stroke Risk Profile with points excluded for age, cognitive 
diagnosis, and separately for APOE4 and APOE2 carrier status; All analyses were re-run 
excluding predictor outliers > 4 standard deviations from mean (n=3), and there were no 
significant changes in results; NFL=neurofilament light 
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Table 3. Model Results Stratified by Cognitive Diagnosis 
 R2 
R2 
adjusted 
*Δ R2 
adjusted 
f2 Partial R2 **P-value 
Cognitively Normal      
†Covariates +       
 Aß42 0.37 0.27 0.05 0.08 0.08 0.02 
 T-tau 0.34 0.24 0.02 0.04 0.04 0.09 
 P-tau 0.34 0.25 0.03 0.05 0.05 0.07 
 NFL 0.31 0.21 -0.009 0.004 0.004 0.62 
Covariates + NFL +       
 Aß42 0.38 0.27 0.06 0.10 0.09 0.01 
 T-tau 0.35 0.24 0.03 0.05 0.05 0.07 
 P-tau 0.35 0.24 0.03 0.05 0.05 0.07 
Covariates + NFL + P-tau + 
 Aß42 0.39 0.28 0.04 0.07 0.07 0.04 
 T-tau 0.35 0.23 -0.01 0.002 0.002 0.71 
Covariates + NFL + T-tau + 
 Aß42 0.40 0.28 0.04 0.08 0.07 0.03 
Mild Cognitive Impairment 
Covariates +       
Aß42 0.27 0.11 -0.004 0.02 0.02 0.38 
T-tau 0.31 0.15 0.04 0.07 0.07 0.08 
P-tau 0.29 0.13 0.02 0.04 0.04 0.17 
NFL 0.35 0.20 0.09 0.13 0.12 0.02 
Covariates + NFL +       
Aß42 0.35 0.19 -0.009 0.01 0.01 0.48 
T-tau 0.36 0.21 0.006 0.03 0.03 0.26 
P-tau 0.36 0.19 -0.006 0.02 0.01 0.42 
Covariates + NFL + P-tau + 
Aß42 0.36 0.18 -0.009 0.01 0.01 0.48 
T-tau 0.37 0.20 0.007 0.03 0.03 0.25 
Covariates + NFL + T-tau + 
Aß42 0.37 0.20 -0.007 0.01 0.01 0.44 
Note. *Represents change in R2 from the covariates only model; **For predictor(s) after 
covariates entered into the model; †includes age, education, sex, race/ethnicity, intracranial 
volume, modified Framingham Stroke Risk Profile with points excluded for age, cognitive 
diagnosis, and APOE4 carrier status; All analyses were re-run excluding predictor outliers 
> 4 standard deviations from mean, and there were no significant changes in results; 
NFL=neurofilament light; p-tau=hyperphosphorylated tau; t-tau=total tau. 
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Figure 1.  Pathophysiology Associated with CSF Biomarkers 
 
Figure 1 Caption. Depictions of pathophysiology associated with each CSF biomarker of 
interest: (1) Aβ42 is a peptide made up of 42 amino acids, which results from cleavage of the 
amyloid precursor protein by beta and gamma secretase, forming larger peptide chains than its 
alpha secretase pathway. These larger peptides misfold into oligomers that form the amyloid 
plaques characteristic of AD. Panel A depicts effective clearance of smaller amyloid peptides 
through perivascular basement membranes. Panel B depicts impaired clearance of large Aβ 
peptides corresponding to increased amyloid deposition in the brain, resulting in Aβ oligomers in 
the extracellular matrix and lower concentrations of Aβ42 in the CSF. (2) Tau is a protein found 
on microtubules that form the intracellular neurofibrillary tangles characteristic of AD. Higher 
CSF concentrations of tau occur in response to neurodegeneration. Hyperphosphorylated tau 
(p-tau) is measured by marking a specific phosphorylation site on the tau protein. P-tau 
measurements are more specific to Alzheimer’s pathology than total tau due to the 
hyperphosphorylation of tau that occurs in AD. As depicted on Panel A, tau may be 
phosphorylated in its normal state and is involved in the dynamic instability of microtubules. 
Panel B illustrates how tau proteins become hyperphosphorylated in AD, causing tau to 
prematurely detach from microtubules and disrupt the balance of assembly and disassembly of 
microtubules. (3) Neurofilament light (NFL) is the smallest and most abundant of three 
polypeptides that form neurofilament proteins found in large-caliber, myelinated axons. As 
depicted in Panel A, neurofilaments exist in the axon alongside microtubules, increasing the 
axon’s diameter and conduction velocity. When axonal damage occurs as illustrated in Panel B, 
neurofilaments spill into extracellular space and are cleared as cellular waste into the CSF. 
Higher CSF concentrations of NFL reflect the acute occurrence of axonal injury. 
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Figure 2. Participant Inclusion/Exclusion Details 
 
Figure 2 Caption. Missing data categories are mutually exclusive. CSF=cerebrospinal fluid; 
FSRP=Framingham Stroke Risk Profile  
Participants Enrolled in the 
Vanderbilt Memory & Aging Project
n=335
Participants 
Included in Analysis
n=153
Participants Exluded for 
Missing Data
CSF Data
n=180
Brain MRI
n=1
FSRP Score
n=1
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Figure 3. CSF Biomarker Concentrations & White Matter 
Hyperintensities 
 
A. Β-Amyloid42 & White Matter Hyperintensities β=-0.001, p=0.003 
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B. Hyperphosphorylated Tau & White Matter Hyperintensities by Amyloid 
Status β=0.002, p=0.55 
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C. Total Tau & White Matter Hyperintensities by Amyloid Status β=0.0004, 
p=0.21 
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D. Neurofilament Light & White Matter Hyperintensities by Amyloid Status 
β=0.0003, p=0.02 
 
Figure 3 Caption. Solid black line reflects unadjusted values of WMH volume (Y axis) 
corresponding to CSF biomarker concentrations (X axis) , including (a) Aβ42, (b) p-tau, (c) t-tau, 
and (d) NFL. WMH=white matter hyperintensities; Aβ42=amyloid-β42; P-
tau=hyperphosphorylated tau; NFL=neurofilament light 
